Free Trial

Xencor (XNCR) Competitors

Xencor logo
$11.00 +0.14 (+1.26%)
As of 12:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XNCR vs. SRRK, AKRO, VKTX, XENE, CPRX, MOR, PTGX, HCM, IMVT, and APLS

Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Scholar Rock (SRRK), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), Protagonist Therapeutics (PTGX), HUTCHMED (HCM), Immunovant (IMVT), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.

Xencor vs.

Scholar Rock (NASDAQ:SRRK) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Scholar Rock had 14 more articles in the media than Xencor. MarketBeat recorded 21 mentions for Scholar Rock and 7 mentions for Xencor. Scholar Rock's average media sentiment score of 1.18 beat Xencor's score of 1.15 indicating that Scholar Rock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
15 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Xencor
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xencor has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$33.19M93.63-$165.79M-$2.45-13.37
Xencor$110.49M6.99-$126.09M-$3.51-3.09

Scholar Rock has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -145.60% -91.83%
Xencor -232.77%-30.92%-21.74%

Scholar Rock presently has a consensus target price of $42.67, suggesting a potential upside of 30.24%. Xencor has a consensus target price of $32.86, suggesting a potential upside of 202.55%. Given Xencor's stronger consensus rating and higher possible upside, analysts plainly believe Xencor is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Xencor
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Scholar Rock has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Xencor received 340 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 73.24% of users gave Xencor an outperform vote while only 66.27% of users gave Scholar Rock an outperform vote.

CompanyUnderperformOutperform
Scholar RockOutperform Votes
169
66.27%
Underperform Votes
86
33.73%
XencorOutperform Votes
509
73.24%
Underperform Votes
186
26.76%

91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.2% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Xencor beats Scholar Rock on 12 of the 19 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XNCR vs. The Competition

MetricXencorPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$772.71M$6.84B$5.53B$7.93B
Dividend YieldN/A3.05%5.11%4.22%
P/E Ratio-3.397.3222.5118.54
Price / Sales6.99241.49397.62103.30
Price / CashN/A65.8538.1834.62
Price / Book0.996.486.734.25
Net Income-$126.09M$143.41M$3.22B$248.18M
7 Day Performance3.33%2.58%1.38%1.03%
1 Month Performance10.59%5.00%2.79%2.70%
1 Year Performance-54.04%-3.72%15.41%4.05%

Xencor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XNCR
Xencor
3.5155 of 5 stars
$11.00
+1.3%
$32.86
+198.8%
-54.6%$780.04M$110.49M-3.43280Upcoming Earnings
Analyst Forecast
Positive News
SRRK
Scholar Rock
4.0538 of 5 stars
$31.67
-3.5%
$42.67
+34.7%
+119.0%$3.00B$33.19M-13.48140Upcoming Earnings
Insider Trade
News Coverage
Positive News
AKRO
Akero Therapeutics
3.7931 of 5 stars
$42.17
+2.9%
$76.29
+80.9%
+125.6%$2.92BN/A-11.2530Upcoming Earnings
News Coverage
Positive News
VKTX
Viking Therapeutics
4.5162 of 5 stars
$25.94
+3.8%
$87.15
+236.0%
-62.6%$2.91BN/A-25.9420Analyst Upgrade
Options Volume
Analyst Revision
XENE
Xenon Pharmaceuticals
2.5671 of 5 stars
$37.84
+0.6%
$56.78
+50.0%
-10.4%$2.90B$9.43M-13.42210Upcoming Earnings
Options Volume
News Coverage
Positive News
CPRX
Catalyst Pharmaceuticals
4.6832 of 5 stars
$23.63
+0.8%
$32.29
+36.6%
+59.7%$2.88B$491.73M20.0380Upcoming Earnings
Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
PTGX
Protagonist Therapeutics
3.4712 of 5 stars
$44.39
-0.2%
$65.44
+47.4%
+76.0%$2.72B$434.43M16.69120Upcoming Earnings
News Coverage
Positive News
HCM
HUTCHMED
1.247 of 5 stars
$15.08
+3.2%
$19.00
+26.0%
-21.1%$2.63B$630.20M0.001,760Upcoming Earnings
Short Interest ↑
IMVT
Immunovant
2.2341 of 5 stars
$15.42
+4.8%
$38.33
+148.6%
-44.2%$2.62BN/A-5.89120
APLS
Apellis Pharmaceuticals
4.1347 of 5 stars
$17.96
+2.7%
$45.35
+152.5%
-56.4%$2.51B$781.37M-8.85770Upcoming Earnings
Analyst Forecast
Analyst Revision
News Coverage

Related Companies and Tools


This page (NASDAQ:XNCR) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners